A one percent reduction in cancer-related deaths in the U.S. would be worth an estimated $500 billion to society from increased quality of life and increased productivity from longer lives.
[ Get More Details ]
According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.… [ Get More Details ]
The increase in the stock of cancer drugs from 1975 to 1995 accounted for about 50 to 60 percent of the increase in age-adjusted survival rates in the first 6… [ Get More Details ]
According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has… [ Get More Details ]
After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who… [ Get More Details ]